DDInter351 DDInter927
An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022]
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Chloramphenicol {u} (Compound) binds {v} (Gene) CYP3A5
Chloramphenicol {u} (Compound) upregulates {v} (Gene) CCNH
Chloramphenicol {u} (Compound) is included by {v} (Pharmacologic Class) Amphenicols
Chloramphenicol {u} (Compound) downregulates {v} (Gene) USP22
Chloramphenicol {u} (Compound) causes {v} (Side Effect) Angioedema
Chloramphenicol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Chloramphenicol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elotuzumab
Chloramphenicol {u} may lead to a major life threatening interaction when taken with {v} Flibanserin
Chloramphenicol (Compound) binds CYP3A5 (Gene)
Chloramphenicol (Compound) upregulates CCNH (Gene)
Chloramphenicol (Compound) is included by Amphenicols (Pharmacologic Class)
Chloramphenicol (Compound) downregulates USP22 (Gene)
Chloramphenicol (Compound) causes Angioedema (Side Effect)
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Donepezil
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Chloramphenicol may lead to a major life threatening interaction when taken with Flibanserin